Evidence map›Paper›PMID 33121182›Full record

ArticleInternational journal of molecular sciences2020

Structural Analysis of Merkel Cell Polyomavirus (MCPyV) Viral Capsid Protein 1 (VP1) in HIV-1 Infected Individuals.

Carla Prezioso, Martina Bianchi, Francisco Obregon, Marco Ciotti, Loredana Sarmati, Massimo Andreoni, Anna Teresa Palamara, Stefano Pascarella, Ugo Moens, Valeria Pietropaolo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Carla PreziosoIRCSS San Raffaele Pisana, Microbiology of Chronic Neuro-degenerative Pathologies, 00163 Rome, Italy.
Martina BianchiDepartment of Biochemical Sciences "A. Rossi Fanelli", "Sapienza" University of Rome, 00185 Rome, Italy.
Francisco ObregonDepartment of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.
Marco CiottiLaboratory of Clinical Microbiology and Virology, Polyclinic Tor Vergata Foundation, 00133 Rome, Italy.ORCID 0000-0002-9943-9130
Loredana SarmatiInfectious Diseases Clinic, Policlinic Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-1452-0333
Massimo AndreoniInfectious Diseases Clinic, Policlinic Tor Vergata, 00133 Rome, Italy.
Anna Teresa PalamaraDepartment of Public Health and Infectious Diseases, Institute Pasteur, Cenci-Bolognetti Foundation, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0001-8330-4381
Stefano PascarellaDepartment of Biochemical Sciences "A. Rossi Fanelli", "Sapienza" University of Rome, 00185 Rome, Italy.ORCID 0000-0002-6822-4022
Ugo MoensDepartment of Medical Biology, Faculty of Health Sciences, University of Tromsø, 9037 Tromsø, Norway.
Valeria PietropaoloDepartment of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.ORCID 0000-0001-5723-8886
Sapienza University of Rome · ITUniversity of Rome Tor Vergata · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITPoliclinico Tor Vergata · ITUiT The Arctic University of Norway · NO

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca RM11916B1DFD19A1
6 · The paper itself

Abstract

Merkel cell polyomavirus (MCPyV) viral protein 1 (VP1) is the capsid protein that mediates virus attachment to host cell receptors and is the major immune target. Given the limited data on MCPyV VP1 mutations, the VP1 genetic variability was examined in 100 plasma and 100 urine samples from 100 HIV+ individuals. Sequencing of VP1 DNA in 17 urine and 17 plasma specimens, simultaneously MCPyV DNA positive, revealed that 27 samples displayed sequences identical to VP1 of MCC350 strain. VP1 from two urine specimens had either Thr47Ser or Ile115Phe substitution, whereas VP1 of one plasma contained Asp69Val and Ser251Phe substitutions plus deletion (∆) of Tyr79. VP1 DNA in the remaining samples had mutations encoding truncated protein. Three-dimensional prediction models revealed that Asp69Val, Ser251Phe, and Ile115Phe caused neutral effects while Thr47Ser and Tyr79∆ produced a deleterious effect reducing VP1 stability. A549 cells infected with urine or plasma samples containing full-length VP1 variants with substitutions, sustained viral DNA replication and VP1 expression. Moreover, medium harvested from these cells was able to infect new A549 cells. In cells infected by samples with truncated VP1, MCPyV replication was hampered. In conclusion, MCPyV strains with unique mutations in the

Indexed as

Amino Acid SubstitutionA549 CellsAdultAgedCapsid ProteinsCross-Sectional StudiesFemaleHIV-1HIV InfectionsHumansMaleMerkel cell polyomavirusMiddle AgedModels, MolecularPlasmaPolyomavirus InfectionsCapsid ProteinsVP1 protein, polyomavirusA549 culture systemamino-acids mutationHIV+ individualsMerkel cell polyomavirus (MCPyV)protein structural organizationviral protein 1 (VP1)

Identifiers

PMID33121182
PMCPMC7663277
OpenAlexW3097306138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.